COMBINATION OF GLIVEC (STI571) WITH A CYCLIN DEPENDENT KINASE INHIBITOR, ESPECIALLY FLAVOPIRIDOL IN CANCER TREATMENT.

摘要

Use of a combination for simultaneous, separate or sequential use comprising (a) a cyclin-dependent kinase inhibitor and (b) 4- (4-methylpiperazin-1-ylmethyl) -N- [4-methyl-3- (4- pyridin-3-yl) pyrimidin-2-ylamino) phenyl] -benzamide having the formula I (See formula) in which the active ingredients (a) and (b) are present in each case in free form or in the form of a pharmaceutically acceptable salt, and optionally, at least one pharmaceutically acceptable carrier, for the preparation of a medicament in the treatment of Bcr / Abl-positive leukemia that is resistant to a compound of formula I.